Medicines Development For Global Health
Clinical trials sponsored by Medicines Development For Global Health, explained in plain language.
-
Could a single pill cure scabies? new study tests three doses
Disease control CompletedThis study tested whether a single dose of an oral drug called moxidectin can cure scabies, a skin condition caused by tiny mites. 200 adults with confirmed scabies received either 8 mg, 16 mg, or 32 mg of moxidectin or a placebo. The main goal was to see if the drug could comple…
Phase: PHASE2 • Sponsor: Medicines Development for Global Health • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug moxidectin put to the test against river blindness in massive safety trial
Disease control CompletedThis large Phase 3 trial compared the safety of a single dose of moxidectin versus ivermectin in nearly 13,000 people living in areas where river blindness is common. Some participants also received albendazole for lymphatic filariasis. The goal was to see if moxidectin causes fe…
Phase: PHASE3 • Sponsor: Medicines Development for Global Health • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
River blindness drug trial aims to find right dose for kids
Disease control CompletedThis study tested a single dose of moxidectin in 36 children aged 4 to 17 who have or are at risk of onchocerciasis (river blindness). The goal was to find a dose for children 4-11 years that works like the standard 8 mg dose used in older kids and adults. Researchers measured dr…
Phase: PHASE1 • Sponsor: Medicines Development for Global Health • Aim: Disease control
Last updated Jun 26, 2026 13:56 UTC